Christopher Downs

Christopher Downs (finance chief) discloses dealings in 3 companies, chiefly CNS Pharmaceuticals, Inc., EBET, Inc. and InfuSystem Holdings, Inc. We count 10 filings; the first trade dates from 14 August 2017 and the latest from 1 February 2024.

Purchases make up the whole of the open-market record (7 purchases, €326k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 1 share grant and 2 option exercises. Since January 2024: 1 purchase and no sales on the market.

A typical purchase (the median) is worth €13k. Of 7 purchases, 4 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 6 February 2024, reports an open-market purchase of €19k in CNS Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.